

RYVU THERAPEUTICS S.A.
Q1 2026 Report

TABLE OF CONTENTS

1. ECONOMIC AND FINANCIAL HIGHLIGHTS

1.1 Financial Results Obtained in the Reporting Period

Condensed Interim Financial Statements of Ryvu Therapeutics S.A. ("Company", "Issuer", "Ryvu") for the period from January 1, 2026, to March 31, 2026, are prepared in accordance with the requirements of the International Accounting Standard No. 34 "Interim Financial Reporting" endorsed by the EU ("IAS 34").

Selected data of the statement of financial position are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**31.03.2026**	31.12.2025	**31.03.2026**	31.12.2025
Total assets	**200,955**	224,436	**46,849**	53,100
Short-term receivables	**22,445**	20,100	**5,233**	4,756
Cash and cash equivalents	**49,696**	59,606	**11,586**	14,102
Other financial assets	**33,409**	48,072	**7,789**	11,373
Total liabilities	**159,629**	170,601	**37,215**	40,363
Long-term liabilities	**107,898**	109,020	**25,155**	25,793
Short-term liabilities	**51,731**	61,581	**12,060**	14,569
Total equity	**41,326**	53,834	**9,635**	12,737
Share capital	**9 248**	9,248	**2,156**	2,188

Selected data of the statement of comprehensive income are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**From 01.01.2026 to 31.03.2026**	From 01.01.2025 to 31.03.2025	**From 01.01.2026 to 31.03.2026**	From 01.01.2025 to 31.03.2025
Revenues from sales	**13,437**	13,419	**3,168**	3,207
Revenues from subsidies	**4,760**	4,101	**1,122**	980
Revenues from R&D projects	**3,514**	3,514	**828**	840
Other operating revenues	**0**	3	**0**	1
Revenues from operating activities	**21,710**	21,037	**5,118**	5,027
Operating expenses	**-33,871**	-58,728	**-7,985**	-14,034
Operating expenses without Incentive Scheme and valuation of NodThera shares	**-33,978**	-47,800	**-8,010**	-11,422
Depreciation	**-2,147**	-2,423	**-506**	-579
Valuation of Incentive Scheme	**-139**	-995	**-33**	-238
Loss from operating activities (EBIT)	**-12,160**	-37,691	**-2,867**	-9,007
Loss from operating activities (EBIT) without Incentive Scheme and valuation of NodThera shares	**-12,267**	-26,763	**-2,892**	-6,395
Loss before income tax	**-12,467**	-25,262	**-2,939**	-6,037
Net loss	**-12,647**	-25,276	**-2,982**	-6,040
Net loss without Incentive Scheme	**-12,508**	-24,281	**-2,949**	-5,802
EBITDA	**-10,013**	-35,268	**-2,361**	-8,428
EBITDA without Incentive Scheme and valuation of NodThera shares	**-10,121**	-24,340	**-2,386**	-5,816
Net cash flows from operating activities	**-22,844**	-44,183	**-5,385**	-10,558
Net cash flows from investing activities	**15,500**	37,164	**3,654**	8,881
Net cash flows from financing activities	**-1,195**	-1,318	**-282**	-315
Total net cash flow	**-8,538**	-8,337	**-2,013**	-1,992
Number of shares (weighted average)	**23,120,148**	23,120,148	**23,120,148**	23,120,148
Profit (loss) per share (in PLN)	**-0.55**	-1.09	**-0.13**	-0.26
Diluted profit (loss) per share (in PLN)	**-0.55**	-1.09	**-0.13**	-0.26
Book value per share (in PLN)	**1.79**	5.54	**0.42**	1.32
Diluted book value per share (in PLN)	**1.79**	5.54	**0.42**	1.32
Declared or paid dividend per share (in PLN)	**-**	-	**-**	-

Selected financial data presented in the quarterly report were converted to Euro as follows:

1. Items relating to the profit and loss statement and the cash flow statement were converted using the exchange rate, constituting the arithmetic average of the exchange rates, applicable as of the last day of every month in the given period, based on the information published by the National Bank of Poland (NBP):
   - for the period from 01/01/2026 – 31/03/2026: PLN 4.2419;
   - for the period from 01/01/2025 – 31/03/2025: PLN 4.1848;
2. Balance sheet items were converted using the average exchange rate announced by the NBP applicable as of the balance sheet date, which were:
   - as of 31 March 2026: PLN 4.2894
   - as of 31 December 2025: PLN 4.2267

1.2 Management Board comments on the financial results

In the first quarter of 2026, Ryvu Therapeutics S.A. recognized total operating revenue of PLN 21,710 thousand, which constitutes an increase compared to the corresponding period in 2025, when total operating revenue amounted to PLN 21,037 thousand. This results from an increase in revenues from subsidies (an increase of PLN 659 thousand), compared to the corresponding period in 2025.

In the first quarter of 2026, Ryvu reported a net loss, as well as an operating loss. The net and operating losses result from the fact that the Company focuses on increasing the value of the ongoing projects that will be commercialized at a later stage of development.

The Company's net loss for the period ended March 31, 2026, amounted to PLN 12,647 thousand and was lower compared to the net loss of PLN 25,276 thousand in the corresponding period of 2025. The Company's operating loss in Q1 2026 decreased by PLN 25,531 thousand compared to the corresponding period of 2025 from PLN 37,691 thousand in Q1 2025 to PLN 12,160 thousand in Q1 2026. Operating costs decreased from PLN 58,728 thousand in Q1 2025 to PLN 33,871 thousand in Q1 2026. The reduction in operating costs reflects a deliberate concentration of resources on the programs with the highest near-term value-creation potential, principally the RIVER-81 Phase II study of romaciclib in relapsed/refractory AML following venetoclax-based therapy failure — a setting with no approved therapeutic option and a median overall survival of under three months. This focus is expected to accelerate the generation of clinical evidence required to support partnering and further development decisions and reinforced by ongoing cost discipline and the strategic reorganization announced in February 2025.

Financing from the European Investment Bank

On August 16, 2022, the Company concluded a financing agreement with the European Investment Bank. Under the agreement, the EIB agreed to grant the Company a loan in the amount of EUR 22,000,000.

The financing was paid in three tranches. The Company is obliged to repay each of the paid tranches in one installment, 5 years after its launch.

In consideration for the financing received, the Company issued to the EIB subscription warrants representing in aggregate 2.5% of the Company's fully issued share capital. The Company undertook to issue 592,825 subscription warrants to the EIB.

Additionally, put option issued by the Company creates a contractual obligation to repurchase its equity instruments (warrants). As of March 31, 2026, Ryvu recognized a positive impact of the put option in the amount of PLN 2,106 thousand.

1.3 The Company's Assets and the Structure of Assets and Liabilities

As of March 31, 2026, the value of the Company's assets was PLN 200,955 thousand and decreased by PLN 23,480 thousand compared to the end of 2025 (PLN 224,436 thousand), mainly due to expenditures incurred on discovery and clinical projects. At the end of March 2026, the highest value of assets was cash, which amounted to PLN 49,696 thousand (at the end of 2025, it was PLN 59,606 thousand), and other financial assets of PLN 33,409 thousand (at the end of 2025, it was PLN 48,072 thousand). Fixed assets are mainly the Research and Development Centre for Innovative Drugs (named 'CBR') and laboratory equipment, as well as the valuation of NodThera shares.

The main item in Ryvu's equity and liabilities is equity, which amounted to PLN 41,326 thousand as of March 31, 2026, and decreased by PLN 12,508 thousand compared to December 31, 2025. The decrease in equity is primarily attributable to the net loss recorded for the period. The other source of funding for assets is long-term liabilities, which amounted to PLN 107,898 thousand as of the end of March 2026. The long-term liabilities are mainly related to the loan received from the European Investment Bank. Additionally, long-term liabilities include deferred income, primarily related to deferred revenue from the BioNTech agreement, as well as the infrastructure subsidy for CBR.

The asset structure demonstrates the Company's high financial liquidity, which is confirmed by the following ratios:

	31.03.2026	31.12.2025
Current ratio current assets/current liabilities, including short-term provisions and accruals (excl. deferred revenues)	2.45	2.45
Quick ratio (current assets-inventory)/current liabilities, including short-term provisions and accruals (excl. deferred revenues)	2.42	2.43

Cash surpluses not utilized in operating activities are invested in low-risk financial instruments, including short-term bank deposits, investment funds, and bonds.

1.4 Current and Projected Financial Condition

The Company maintains adequate liquidity to fund its planned operations, supported by its current cash position and the financing received from the European Investment Bank. The Company continues to evaluate additional non-dilutive financing options to support the clinical development of romaciclib and other pipeline programs.

As of March 31, 2026, the value of the Company's cash amounted to PLN 83,100 (PLN 49,696 thousand in cash at the banks and PLN 33,404 thousand in investment funds), and as of May 15, 2026, it was PLN 74,640 thousand (PLN 45,899 thousand in cash at the banks and PLN 28,741 thousand in investment funds). The decrease in cash resulted from expenditure incurred on early pipeline and clinical development projects.

Ryvu continues to advance three key strategic collaborations, under which all incurred costs are fully reimbursed, and the Company remains eligible to receive multiple financial milestones: Menarini, relating to JASPIS-01; BioNTech, relating to discovery programs; and Exelixis, relating to STING-agonist-based ADCs.

Ryvu is also developing its clinical execution division, which supports clinical research activities conducted by Ryvu, BioNTech and Menarini. The Company expects this division to generate increased revenue from existing external partners and from the gradual expansion of its customer portfolio.

These partnerships are important because they provide validation of Ryvu's scientific platform, reduce internal funding requirements, and create the potential for milestone-driven upside.

In parallel, Ryvu continues to engage with potential partners for its fully owned programs.

Cash inflow from previous share issues, funds obtained from EU subsidies, financing received from the EIB, funds supporting R&D projects, and cash generated from the commercialization of projects enable

the Company to execute its planned investments, particularly the development of ongoing and new innovative projects and the expansion of laboratory infrastructure. The Company's future revenues will strongly depend on the ability to commercialize its R&D projects.

The Company may obtain additional non-dilutive financing from multiple sources, among others:

- potential strategic and financial partners,
- financial milestones and research funding from current collaborations,
- new projects with current and new partners (including Ryvu's clinical execution division).

2 MANAGEMENT BOARD INFORMATION ON ACTIVITIES

2.1 The pipeline

Ryvu Therapeutics is advancing a broad pipeline addressing emerging targets in oncology.

Ryvu's pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinases, synthetic lethality, immuno-oncology, and immunometabolism pathways. These research and development projects are represented below.



Source: Company's data.

Romaciclib (RVU120)

Romaciclib (RVU120) is a clinical-stage, selective, first-in-class dual inhibitor of CDK8 and CDK19 kinases. The international nonproprietary name of romaciclib was assigned to RVU120 by the WHO and announced on the proposed list in February 2025, followed by the publication of the INN Recommended List 94 on November 3, 2025. Romaciclib has demonstrated efficacy in several solid tumors and hematologic malignancies in *in vitro* and *in vivo* models. CDK8 and its paralog, CDK19, are kinase submodules of the mediator complex, involved in both transcriptional activation and repression, playing central roles in maintaining the viability of cancer cells and their undifferentiated state across various tumor types (Dannappel et al., 2019; Rzymski et al., 2015; Philip et al., 2018). CDK8/19 mediator complex integrates basal transcriptional machinery with the activity of oncogenic transcriptional and epigenetic factors. Inhibition of CDK8/19 can repress key oncogenic transcriptional programs and induce lineage commitment genes in acute myeloid leukemia (AML).

Romaciclib has been internally discovered by Ryvu and has received support from the Leukemia & Lymphoma Society Therapy Acceleration Program® (TAP), a strategic initiative to partner directly with innovative biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers.

On March 25, 2020, the U.S. Food and Drug Administration (FDA) granted romaciclib an orphan drug designation (ODD) for the treatment of patients with AML.

Based on the available translational and clinical data, Ryvu is executing a Clinical Development Plan (CDP) for romaciclib with focus on hematologic malignancies. Additionally, an investigator-initiated Phase I study to evaluate romaciclib in combination with everolimus in pediatric patients with medulloblastoma (MEDWAY) was announced in September 2025. The MEDWAY project will be executed by the Children's Memorial Health Institute (IPCZD) as a sponsor of the study under an approx. PLN 40 million grant awarded by the Polish Medical Research Agency. Romaciclib's development in a pediatric indication may qualify for a Rare Pediatric Disease Priority Review Voucher (PRV) from the U.S. Food and Drug Administration upon regulatory approval. PRVs, which are freely transferable and represent material potential upside to Ryvu at no additional cost to the Company, as the MEDWAY study is grant-funded.

Three clinical studies with romaciclib have completed enrollment and all patients have discontinued study treatment: (i) Phase Ib in patients with AML/HR-MDS (NCT04021368; CLI120-001, RIVER-51), (ii) Phase I/II in patients with relapsed/refractory metastatic or advanced solid tumors (NCT05052255; RVU120-SOL-021, AMNYS-51), and (iii) Phase II in patients with AML/ HR-MDS (NCT06268574; RIVER-52).

Three additional clinical studies have presented preliminary results in the reporting period:

RIVER-81 Phase II study

On January 31, 2024, Ryvu announced the dosing of the first patient in the RIVER-81 Phase II study of romaciclib in combination with venetoclax (NCT06191263). RIVER-81 is a multicenter, open-label clinical trial that aims to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of romaciclib when administered in combination with venetoclax to patients with AML who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent.

During the American Society of Hematology (ASH) Annual Meeting in December 2025 in Orlando, a data update was provided. A total of 58 patients had been dosed with romaciclib in combination with venetoclax and the study is ongoing. Romaciclib in combination with venetoclax was generally tolerated in this difficult-to-treat population. No dose-limiting toxicities were observed up to romaciclib 200 mg QD combined with venetoclax 400 mg QD, and no new safety signals were identified. A dose of 250 mg QD was tested but was associated with poor tolerability.

An abstract was accepted for poster presentation at the upcoming European Hematology Association (EHA) Congress in June 2026 in Stockholm, Sweden. This poster will present longer follow-up data. At the 150 mg QD + VEN 400 mg dose level, the composite CR rate was 43% (3/7), including 2 CRs and 1 CRi. Across other dose levels, 6 CRh/CRi responses were reported in 51 treated patients.

The execution of the RIVER-81 study is supported by a PLN 62.3 million grant from the Polish Medical Research Agency (ABM).

POTAMI-61 Phase II study

The Phase II POTAMI-61 study (NCT06397313) investigates romaciclib as both a monotherapy and a combination therapy for treating patients with myelofibrosis (MF). In Part A, Cohort 1 assesses romaciclib as a monotherapy in patients who have been previously treated with or are ineligible for

treatment with a JAK inhibitor, and Cohort 2 assesses romaciclib in combination with ruxolitinib in patients experiencing a suboptimal response to JAK inhibitor therapy.

Romaciclib's potential in myelofibrosis is supported by its effect on bone marrow and hematopoietic cells observed in the clinical trial setting, as well as in translational data generated with Prof. Rajit Rampal at the Memorial Sloan Kettering Cancer Centre as part of a collaboration with Ryvu established in 2021. It was demonstrated that romaciclib successfully attenuates myelofibrosis phenotypes, either as a single agent or in combination with ruxolitinib, in murine models of myelofibrosis. Furthermore, romaciclib was shown to act synergistically with a whole class of JAK inhibitors and the BET inhibitor pelabresib.

The POTAMI-61 study was launched at clinical sites in Poland and Italy, and on December 5, 2024, the first patient received treatment.

An update was presented at the ASH Annual Meeting in Orlando in December 2025 showing the outcome of 25 treated patients.

An abstract was accepted for poster presentation at the EHA Congress in Stockholm. Twenty-eight patients were treated with romaciclib as a single agent (Cohort 1) or in combination with ruxolitinib (Cohort 2). Seven patients across cohorts achieved ≥10% spleen volume reduction (SVR). All three patients with ASXL1 mutation demonstrated SVR, including one patient with 59% SVR and bone marrow fibrosis reduction. Clinically meaningful and durable symptom improvements were observed in some patients. Platelet counts remained stable throughout treatment, including in cytopenic patients. In selected patients, an increase of erythropoietic progenitors were observed with hemoglobin increase (>2 g/dL in one case) and reduction in transfusion burden. Grade 1 or 2 nausea and vomiting were the most common TEAEs. No overlapping hematologic toxicity with ruxolitinib was observed.

Following the completion of Part A (23 patients) of the study and initial enrollment in Part B (5 patients), Management Board of the Company has decided not to proceed with further enrollment, closing the study at 28 patients. The decision to discontinue enrolment was not based on any safety concerns. Patients, who are currently participating in the study and deriving clinical benefit from romaciclib according to investigators' assessment, will continue to receive treatment in a new roll-over study (ROVER-01), in accordance with the applicable regulatory and ethical requirements. The Company will analyze data from POTAMI-61 to inform potential future myelofibrosis development decisions and retain the option to resume a modified myelofibrosis development. The Company decided to prioritize romaciclib's development on acute myeloid leukemia (AML), particularly in patients with relapsed/refractory AML following venetoclax-based regimens, which represents the area of greatest unmet medical need and most compelling clinical data observed to date. This approach is intended to preserve strategic optionality for romaciclib while focusing resources in the short term on the clinical dataset that is expected to be most relevant for potential development partners for romaciclib.

REMARK Phase II study

The Phase II REMARK study (NCT06243458) is being conducted as an investigator-initiated trial within the European Myelodysplastic Neoplasms Cooperative Group (EMSCO), with Prof. Uwe Platzbecker serving as the Coordinating Principal Investigator. This study explores romaciclib as a monotherapy for the treatment of patients with low-risk myelodysplastic syndromes (LR-MDS). The REMARK study has

commenced enrollment of patients across five countries: Poland, Germany, France, Spain and Italy, with a total of 20 clinical sites initiated across these countries. The planned overall enrollment in the study was set at approximately 40 patients. The first patient in the REMARK study was treated on September 19, 2024, and enrollment was completed in May 2025.

At the ASH Annual Meeting in December 2025 in Orlando, 42 patients with LR-MDS were treated in the REMARK study. No new safety signal was identified with romaciclib. Nausea and vomiting were the most common adverse events. At the interim analysis to assess stage 1 of Simon's two-stage design, 2 of the first 21 patients treated achieved an erythroid response, and the study passed the pre-specified futility criterion. Additional clinical, molecular, and translational data will be collected in more patients and with longer follow-up to determine the activity of romaciclib in this population or in a subgroup of patients.

Dapolsertib (MEN1703, SEL24)

Dapolsertib (also known as MEN1703 or SEL24) is a selective, small-molecule dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells and lymphomagenesis. The compound has been discovered by Ryvu and is currently in clinical development in collaboration with Menarini Group as a therapeutic option for various cancers. The licensing agreement with Menarini was executed in March 2017. Initially, dapolsertib was developed as a potential treatment for patients with relapsed/refractory acute myeloid leukemia (AML). More details of the completed Phase I/II clinical study are available at ClinicalTrials.gov under the identifier NCT03008187. Data from this part of the study were presented at multiple scientific conferences and symposia. Ryvu has been supporting this project with translational research.

Based on a decision announced in September 2023, Menarini continues the development of dapolsertib by initiating a new Phase II study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) – JASPIS-01 study. Menarini fully funds all study activities, while Ryvu acts as the operational partner to execute the JASPIS-01 study on behalf of Menarini. The licensing partnership with Menarini, including the total milestones and royalties due to Ryvu upon the achievement of certain events, remains unchanged.

The JASPIS-01 study is an open-label, Phase II clinical trial investigating dapolsertib as a monotherapy and in combination with glofitamab for patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). It comprises three parts: Part 1 focuses on evaluating safety and preliminary anti-lymphoma activity in approximately 18 patients; Part 2, based on Part 1 results, will assess anti-tumor activity as a primary objective in a larger group of patients, as well as safety and tolerability; and Part 3 will offer an optional randomized comparison.

The JASPIS-01 study was initiated in Q4 2024. On March 26, 2025, Ryvu announced dosing of the first patient. The study was initiated at clinical sites in Poland. It is also currently recruiting in France, Spain, and the United Kingdom. The study is registered on ClinicalTrials.gov under NCT06534437.

At the ASH Annual Meeting in December 2025, a Trial-in-Progress poster was presented. At this time, 11 patients had been enrolled across the combination and monotherapy cohorts.

BioNTech: Clinical collaboration

In September 2025, Ryvu concluded a strategic agreement with BioNTech to provide specialized services to accelerate site activation and patient enrolment for several of BioNTech's priority oncology

clinical programs in Poland, covering indications such as lung, breast, and colorectal cancers. Under the agreement, both parties leverage Ryvu's operational excellence, extensive expertise in oncology clinical operations, and established trial site network to enhance and streamline access for Polish patients to BioNTech's investigational immunotherapies.

PRECLINICAL AND DISCOVERY STAGE PROJECTS

The Company continues to execute its strategy across two core discovery and development platforms, each with the potential to generate multiple oncology therapeutic opportunities, novel small molecules and novel ADC payloads.

This strategy supports a diversified early-stage pipeline while maintaining focus on areas where Ryvu has established scientific expertise and partnering potential.

Thanks to its ongoing strategic collaborations, Ryvu's early-stage projects are currently additionally funded through commercial revenues and non-dilutive grants.

Synthetic lethality projects

RVU305 Oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor in IND/CTA-enabling studies

RVU305 is a potentially best-in-class, oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor, currently in the IND/CTA-enabling phase. It is designed to target cancers characterized by the deletion of the MTAP metabolic gene, a genetic alteration found in approximately 10–15% of all human tumors. RVU305 leverages this vulnerability as an MTA-cooperative PRMT5 inhibitor, selectively impeding the growth of cancer cells harboring MTAP deletions.

In Q1 2026, RVU305 achieved key preclinical milestones, including completion of toxicology studies and API/IMP manufacturing. Non-clinical GLP-toxicology studies were completed in two species with a favorable safety profile and no major toxicology findings; these data will inform the calculation of the first-in-human (FIH) starting dose. In parallel, synthesis of a GMP batch as well as manufacturing of the final clinical-trial drug product were completed.

Building on these results, Ryvu is currently preparing the documentation package required for the submission of a Clinical Trial Application (CTA) to the relevant Regulatory Authority.

Novel Multi-Target-Discovery

ONCO Prime – Novel Small Molecule Precision Oncology

Ryvu is accelerating internal initiatives to identify and validate novel synthetic lethal and precision oncology targets for first-in-class small-molecule drug discovery programs. In June 2024, Ryvu finalized a funding agreement with the Polish Agency for Enterprise Development (PARP) and expects to receive approximately $6.6 million (PLN 26.3 million) in grant funding over five years to support the proprietary ONCO Prime discovery platform. The Company is utilizing these funds to accelerate the development of ONCO Prime, including expanding its primary biobank and target discovery efforts across several cancers with the highest population burden, such as colorectal cancer, lung adenocarcinoma, and triple-negative breast cancer (TNBC). The ONCO Prime focuses exclusively on indications with high incidence and epidemiological significance, excluding rare cancers, which are being addressed by the PANACEA-NOVO project submitted to NCBR in February 2026, using a novel technology approach.

Additionally, in March 2026 Ryvu has successfully secured additional funding through a PERO grant (19.96 M PLN), technological functional mapping initiative that goes beyond the R&D scope of ONCO Prime and represents the next step and a key complement to the internal drug discovery process. This additional support will enable expanded functional analysis of newly identified targets and accelerate the identification of small-molecule modulators, thereby advancing the most promising findings into first-in-class discovery programs.

Through the ONCO Prime platform, we have successfully identified new precision oncology targets in colorectal cancer and are advancing small-molecule programs in this area. Ryvu presented recent progress on the ONCO Prime platform at the American Association for Cancer Research in San Diego and the 3rd CRISPR MEDiCiNE Conference in Copenhagen in April 2026.

ADC – Novel ADC payloads

Ryvu continues to leverage expertise in small-molecule drug discovery and therapeutic target selection to develop capabilities in small-molecule payloads and antibody–drug conjugates (ADCs). Building on the success of its collaboration with Exelixis, the Company is advancing additional payload and ADC programs designed to improve efficacy and safety compared with conventional chemotherapy-based approaches. The Company's research activities include cytotoxic, immuno-cytotoxic and other innovative payloads across key therapeutic areas and are supported by a recently filed patent covering a novel, proprietary payload.

STING agonist ADC collaboration with Exelixis

In July 2022, Ryvu signed a licensing agreement with Exelixis to collaborate on novel targeted therapies based on the advanced STING agonist technology developed at Ryvu. To date, Ryvu has received USD 3 million from Exelixis as an upfront payment and an additional USD 3 million in milestone payments upon achievement of certain development milestones. The partnership has developed highly potent STING-activating antibody-drug conjugates that demonstrate picomolar in vitro activity and antigen-specific activation of the STING pathway; further development of these compounds is currently ongoing. The project's current progress remains confidential.

BioNTech: Multi-target research collaboration

In November 2022, BioNTech and Ryvu initiated a comprehensive, multi-target research collaboration to advance small-molecule programs focused on immune modulation in cancer and potentially other disease areas. Under this partnership, BioNTech has the right to acquire global development and commercialization rights for these programs. On March 16, 2026, Ryvu informed about amending its research collaboration option exclusive license agreement with BioNTech. Under the amendment, the parties agreed to extend its research collaboration by an additional period of one year until November 2028. While multiple research initiatives are underway as part of this collaboration, detailed information about these programs remains confidential.

2.2 Significant events in Q1 2026

A) DURING THE REPORTING PERIOD

RVU120 update on Food and Drug Administration (FDA) Type C meeting regarding romaciclib (RVU120)

On January 16, 2026, the Company received the minutes of the Type C meeting with the U.S. Food and Drug Administration, which was held on January 13, 2026, regarding the component of the romaciclib (RVU120) development program related to its combination with venetoclax for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML) following failure of venetoclax in combination with a hypomethylating agent. This indication is currently being tested in the RIVER-81 study. The other indications in which romaciclib is being developed by Ryvu were not discussed at this meeting.

The purpose of the meeting, which was held at Ryvu's request, was to obtain the FDA's feedback on the further clinical development of romaciclib in patients with R/R AML in the United States, with respect to the observed benefit-risk profile. Ryvu also asked for guidance on dose optimization and design assumptions for future registrational clinical studies.

The FDA raised no objections to opening the expansion cohort in the United States with romaciclib at a dose of 150 mg once daily (QD- once a day) in combination with venetoclax, which was assessed in Cohort 4 of the RIVER-81 study.
At the same time, the FDA provided the Company with general guidance regarding:

- expectations related to dose optimization based on an integrated analysis of safety, pharmacokinetic, and pharmacodynamic data;
- clinical trial design for combination therapies, including the standard approach involving randomization in studies with registrational intent;
- the need for further clinical data generation prior to defining a registration pathway.

Next Steps
Following the FDA meeting, the Management Board of the Company plans to undertake the steps required to initiate the dose expansion of romaciclib at 150 mg QD in the United States, including:

- updating the RIVER-81 study protocol, including clarification of safety criteria and the rationale for dose and regimen selection;
- submission of updated documentation to the FDA under the existing Investigational New Drug (IND) application, in line with the feedback received;
- initiation of patient enrollment in the U.S. expansion cohort following completion of the above regulatory steps.

After obtaining more mature clinical data from the expansion stage, the Company plans to hold a subsequent regulatory meeting with the FDA to discuss the further clinical development strategy for the romaciclib program in the aforementioned regulatory pathway.

Conclusion of a grant agreement with the National Centre for Research and Development

On March 11th, 2026, the Company has concluded a grant agreement (the “Agreement”) with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju, “NCBR”) for the co-financing of the Company’s project entitled: “PERO - Predictive Engineering for Rational Oncology: functional mapping of therapeutic targets in oncology" ("Project"). The Agreement was concluded as a result of a call for proposals organized by the National Centre for Research and Development for entrepreneurs aimed at the development of critical technologies and technologies intended to protect and strengthen relevant critical technology value chains in the biotechnology sector under the European Funds for a Modern Economy Programme (FENG), Priority 5: Support for projects contributing to the objectives of the STEP initiative, FENG.05.01-IP.01-001/25 call - Track A: Projects implemented in the biotechnology sector.

The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data.

- the total net value of the Project is: PLN 32,350,211.50;
- recommended amount of the funding: PLN 19,956,904.12;
- the planned duration of the Project: 51 months.

The funding granted under the Agreement will reduce the use of the Company's own funds.

Extension of the Research Collaboration Option and Exclusive License Agreement with BioNTech SE

On March 15, 2026, Ryvu and BioNTech SE, with its registered office in Mainz, Germany (“BioNTech”), have entered into Amendment No. 1 to the research collaboration option and exclusive license agreement dated November 29, 2022 (“License Agreement”). The conclusion of the License Agreement was disclosed by the Company in its Current Report No. 26/2022 dated November 30, 2022.
Under the Amendment, the parties agreed, among others, to extend the term of the research collaboration conducted under the License Agreement by an additional period of one year i.e. until November 29, 2028.
The remaining key terms of the License Agreement, including the economic terms of the collaboration and the funding by BioNTech of discovery, research and development activities thereunder, remain unchanged.

B) EVENTS OCCURRED BETWEEN THE END OF THE REPORTING PERIOD AND THE APPROVAL OF THE FINANCIAL STATEMENT

Poster presenting preclinical data for the ONCO Prime platform at the AACR Annual Meeting 2026

On April 20, 2026, during the AACR Annual Meeting held on April 17–22, 2026 in San Diego, California, the Company presented preclinical data for the ONCO Prime platform.

Details on the poster presentation are as follows:

Abstract Title: "ONCO Prime platform enables discovery of synthetic lethal targets for genetically stratified cancers"
Poster Number: 2989
Session date and time: 20/04/2026, 2:00 PM - 5:00 PM EST

Colorectal cancer (CRC) remains a leading cause of cancer mortality, underscoring the need for new, mechanism-based therapeutic strategies. Using the ONCO Prime discovery and validation platform, based on genome-wide CRISPR/Cas9 screenings across clinically relevant models, we identified novel treatment options for genetically stratified CRC patients.

The ONCO Prime platform integrates healthy human intestinal stem cells (hISCs), isogenic CRC models carrying key driver mutations (*APC*, *KRAS*), and patient-derived primary cultures. All types of models can be genetically manipulated or used in the high-throughput setting for drug screening. Transcriptomic and machine learning analyses confirmed that these models faithfully recapitulate CRC molecular diversity and clinical behavior.

Systematic CRISPR/Cas9 loss-of-function screenings revealed multiple synthetic lethal (SL) interactions, uncovering target genes with first-in-class therapeutic potential. Additionally, using a clinical-grade drug that is FDA-approved in other indications, we achieved proof of concept in genetically stratified CRC models, demonstrating strong efficacy as monotherapy in vitro. These data validate ONCO Prime's translational capability to uncover clinically actionable vulnerabilities and deliver tangible therapeutic candidates.

This work provides a robust foundation for drug discovery programs and strategic partnerships built on ONCO Prime's ability to bridge functional genomics with therapeutic development. Our first proof of concept establishes ONCO Prime as a scalable platform to drive the next generation of precision, first-in-class oncology therapies.

The abstract is now available online and can be obtained from the conference site: https://www.aacr.org/

Clinical data on romaciclib to be presented at the 2026 European Hematology Association Congress

On May 12, 2026 the Company announced that it will present romaciclib (RVU120) clinical data at the European Hematology Association Congress (EHA), June 11-14, 2026, in Stockholm, Sweden.

Details on the abstract presentations are as follows:

Title: Updated findings from the phase 2 RIVER-81 study of romaciclib (RVU120) combinedwith venetoclaxin acute myeloid leukemia after first-line venetoclax
and hypomethylating agent failure
Session date and time: Friday, June 12 (6:45 - 7:45 PM CEST)

Venetoclax (VEN) combined with hypomethylating agents is the standard first-line treatment for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy, yet ~70% experience relapsed/refractory disease with a median survival of under 3 months. Romaciclib, a first-in-class CDK8/CDK19 inhibitor, has shown single-agent activity in AML and preclinical synergy with VEN through enhanced apoptotic signaling and attenuation of resistance pathways.

In the ongoing Phase 2 RIVER-81 trial, romaciclib in combination with VEN demonstrates anti-leukemic activity in patients with poor prognostic AML, with the most consistent responses at romaciclib 150 mg QD + VEN 400 mg QD, including durable CR/CRi, reported with a cut-off date

of 09 February 2026. Based on safety, PK, and preliminary efficacy findings, this regimen was selected as the recommended dose for expansion. Further evaluation is planned to better define durability of response and clinical benefit.

Title: Romaciclib (RVU120), a selective CDK8/19 inhibitor, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis: Updated results from the phase II **POTAMI-61** study
Session date and time: Saturday, June 13 (6:45 - 7:45 PM CEST)

Myelofibrosis (MF) is driven by dysregulated JAK/STAT signaling, and while JAK inhibition with ruxolitinib (RUX) improves splenomegaly and symptoms, cytopenias and suboptimal responses remain clinical challenges. Romaciclib (RVU120) is a first-in-class, oral CDK8/19 inhibitor that modulates STAT-dependent transcription and showed synergy with RUX in preclinical MF models.

In the ongoing Phase II POTAMI-61 study, romaciclib administered as monotherapy or combined with RUX demonstrates a manageable safety profile in patients with MF without significant treatment-related cytopenias. Prolonged exposure, spleen volume reductions, including in patients with high-molecular-risk mutations, and favorable hematologic tolerability support continued clinical development and further evaluation in expansion cohorts.

The abstracts are now available online and can be obtained from the conference site: https://ehaweb.org/

2.3 Unusual events occurring in the reporting period

Not applicable.

3. THE ISSUER'S CORPORATE BODIES

Issuer's Management Board:

1) Paweł Przewięźlikowski – President of the Management Board
2) Krzysztof Brzózka – Vice President of the Management Board
3) Kamil Sitarz – Member of the Management Board
4) Vatnak Vat-Ho – Member of the Management Board
5) Hendrik Nogai – Member of the Management Board
6) Justyna Żółtek – Member of the Management Board

Issuer's Supervisory Board:

1) Piotr Romanowski – Chairman of the Supervisory Board
2) Tadeusz Wesołowski – Vice Chairman of the Supervisory Board
3) Rafał Chwast – Supervisory Board Member
4) Axel Glasmacher – Supervisory Board Member
5) Thomas Turalski – Supervisory Board Member
6) Scott Z. Fields – Supervisory Board Member
7) Peter Smith – Supervisory Board Member

Issuer's Audit Committee:

1) Rafał Chwast – Chairman of the Audit Committee
2) Piotr Romanowski – Member of the Audit Committee
3) Tadeusz Wesołowski – Member of the Audit Committee

The Company's Remuneration Committee:

1) Piotr Romanowski – Chairman of the Remuneration Committee
2) Axel Glasmacher – Member of the Remuneration Committee
3) Thomas Turalski – Member of the Remuneration Committee

4. INFORMATION ON THE SHAREHOLDERS HOLDING (DIRECTLY OR INDIRECTLY) AT LEAST 5% OF THE TOTAL NUMBER OF VOTES AT THE GENERAL SHAREHOLDERS' MEETING OF THE COMPANY AND ON SHARES HELD BY MEMBERS OF THE ISSUER'S MANAGEMENT BOARD AND SUPERVISORY BOARD

Shares held by members of the Management and Supervisory Board of the Company as of the date of publication of the Report

Shareholder	Preferred shares*	Ordinary shares	Number of shares	% of Share Capital	Number of Votes	% of Votes at SM
The Management Board						
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)	3 500 000	482 160	**3 982 160**	17,22%	**7 482 160**	27,54%
Krzysztof Brzózka		267 321	**267 321**	1,16%	**267 321**	0,98%
Kamil Sitarz		39 230	**39 230**	0,17%	**39 230**	0,14%
Vatnak Vat-Ho		44 500	**44 500**	0,19%	**44 500**	0,16%
Hendrik Nogai		22 500	**22 500**	0,10%	**22 500**	0,08%
Justyna Żółtek		18 265	**18 265**	0,08%	**18 265**	0.07%
The Supervisory Board						
Tadeusz Wesołowski (directly)		92 975	**92 975**	0,40%	**92 975**	0,34%
Tadeusz Wesołowski (indirectly through Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)		1 279 738	**1 279 738**	5,54%	**1 279 738**	4,71%
Rafał Chwast		121 115	**121 115**	0,52%	**121 115**	0,45%
Thomas Turalski		20 100	**20 100**	0,09%	**20 100**	0,07%

**A single Series A share entitles to two votes at the Shareholder Meeting..*

Shares held by members of the Management and Supervisory Board of the Company as of 31.03.2026

Shareholder	Preferred shares*	Ordinary shares	Number of shares	% of Share Capital	Number of Votes	% of Votes at SM
The Management Board						
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)	3 500 000	482 160	**3 982 160**	17,22%	**7 482 160**	27,54%

Krzysztof Brzózka	267 321	**267 321**	1,16%	**267 321**	0,98%
Kamil Sitarz	39 230	**39 230**	0,17%	**39 230**	0,14%
Vatnak Vat-Ho	57 000	**57 000**	0,25%	**57 000**	0,21%
Hendrik Nogai	22 500	**22 500**	0,10%	**22 500**	0,08%
Justyna Żółtek	18 265	**18 265**	0,08%	**18 265**	0.07%

The Supervisory Board					
Tadeusz Wesołowski (directly)	92 975	**92 975**	0,40%	**92 975**	0,34%
Tadeusz Wesołowski (indirectly through Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)	1 279 738	**1 279 738**	5,54%	**1 279 738**	4,71%
Rafał Chwast	121 115	**121 115**	0,52%	**121 115**	0,45%
Thomas Turalski	20 100	**20 100**	0,09%	**20 100**	0,07%

**A single Series A share entitles to two votes at the Shareholder Meeting..*

Shares held by significant shareholders of the Company as of 31.03.2026 and as of the date of publication of the Report

Shareholder	Shares	% [Shares]	Votes	% [Votes]
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)	3 982 160	17,22%	7 482 160	27,54%
Bogusław Sieczkowski (through CapitalS Fundacja Rodzinna w organizacji)	825 348	3,57%	1 375 348	5,06%
Tadeusz Wesołowski (with Fundacja Rodzinna Rodziny Wesołowski Fundacja Rodzinna w Krakowie)	1 372 713	5,94%	1 372 713	5,05%
Nationale Nederlanden OFE	1 385 262	5,99%	1 385 262	5,10%
Allianz Polska OFE	2 132 540	9,22%	2 132 540	7,85%
BioNTech SE	1 917 437	8,29%	1 917 437	7,06%

The above information regarding the ownership of the Issuer's shares by shareholders (including members of the Company's Management Board and Supervisory Board) holding directly or indirectly at least 5% of the total number of votes at the Company's General Meeting has been prepared based on information received from shareholders in fulfilment of obligations imposed on shareholders of public companies under applicable legal regulations, including the provisions of the Act of 29 July 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies (Articles 69 et seq.). Information concerning holdings of members of the Company's Management Board and Supervisory Board has additionally been prepared based on notifications submitted pursuant to Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR).

In addition, information regarding ownership of the Company's shares may also be based on publicly available information concerning holdings and asset structure of investment funds and pension funds, including information regarding the number of shares registered for participation in the Company's General Meeting. Such data is published periodically, including in financial statements of investment funds and pension funds, and may change following publication of the most recent available information.

5. STATEMENT OF THE MANAGEMENT BOARD REGARDING APPLICABLE ACCOUNTING PRINCIPLES

The Management Board of Ryvu Therapeutics S.A. confirms that, to the best of its knowledge, the quaterly financial statements have been prepared in accordance with the applicable accounting principles and reflect in a true, reliable, and transparent manner the financial situation of Ryvu Therapeutics S.A. and its financial results. The report of the Management Board on the activities of Ryvu Therapeutics S.A. contains a true picture of the development and achievements, including a description of the basic threats and risks.

6. ADDITIONAL INFORMATION

Proceedings pending at court, before an arbitration institution, or a public administration authority

The Company has filed a lawsuit against DUNA POLSKA S.A. (formerly: Mota-Engil Central Europe S.A.) ("Contractor") to the Regional Court in Kraków concerning the construction of the Research and Development Center under the agreement for "Construction of the Research and Development Center of Innovative Drugs Selvita S.A." dated August 13, 2018 ("Construction Agreement"). The claims include payment of contractual penalties for failure to meet the final and intermediate deadlines, as well as for rectification or untimely rectification of defects related to the scope of the Construction Agreement, totalling PLN 13,756,717.07. The total value of the Construction Agreement was PLN 68,783.585.34, including VAT. The proceedings are taking place before the District Court in Kraków in the first instance. On July 8, 2024, the Court concluded the oral hearings of the witnesses and the Parties, simultaneously requiring the Parties to pay advances toward the expert's opinion (by July 22, 2024) and to inform the Court of the mutually agreed-upon candidates for experts (by September 1, 2024). The Parties responded to the Court's request on the above-mentioned dates. The Parties responded to the Court's request within the above-mentioned deadlines. Subsequently, the Court requested the Parties to take a position on the offer of the expert selected by the Parties, who will prepare an opinion within the scope of the evidence outlined by the Parties. Both Parties accepted the offer. The files have been sent to an expert who will prepare an opinion based on the questions outlined by the Parties.

The Contractor has filed a lawsuit for payment against the Company to the Regional Court in Kraków in connection with the performance of the Construction Agreement for the project entitled: "Construction of the Research and Development Center for Innovative Drugs Selvita S.A." In the lawsuit, the Contractor is claiming damages for the costs incurred in connection with prolonged performance of the Construction Agreement, the unpaid portion of the lump sum fee as well as supplementary remuneration for additional, replacement and omitted works (PLN 5,391,425.63) as well as damages resulting from the Company's unauthorized - in the Contractor's opinion - application of the performance bond and removal of the defects and faults (PLN 2,063,507.56). With the statutory interests, the Contractor demands a total amount of PLN 7,671,285 from the Company. On 22 November 2023, the hearings of all witnesses and parties were completed. Subsequently, the files were forwarded to a court expert for the preparation of an opinion. On 8 April 2025, the expert's opinion was delivered to the Company, to which the Parties submitted objections in a procedural letter dated 30 May 2025. The expert responded to the objections and submitted an offer to prepare a supplementary opinion. Currently, the Parties are in the process of agreeing on the scope of the supplementary opinion, which will then be prepared by the expert.

Significant non-arm's-length transactions with related entities

Not applicable.

Information on organizational or capital relations of the Issuer with other entities

As of the report's publication date, the Issuer does not form a Capital Group. As of the date of this Report, the Issuer holds 1.2% of shares in NodThera Inc.

Warranties for loans and borrowings and guarantees granted

Not applicable.

Other information significant for the assessment of the Issuer's position in the area of human resources, assets, cash flows, financial results and changes thereof and information significant for the assessment of the Issuer's ability to settle its liabilities

Not applicable.

Factors which, in the Issuer's opinion, will affect the results over at least the following quarter

The results of the subsequent quarters will depend primarily on the execution of the Company's strategy, which assumes in particular that the following business objectives will be met:

- Advancing romaciclib (RVU120) through Phase II clinical development in relapsed/refractory AML following failure of venetoclax-based regimens — an indication with significant unmet medical need and no approved standard of care — with the objective of generating the clinical data required to define a registration pathway and support potential partnering transactions; the Company continues to evaluate options for future romaciclib development in additional hematologic indications based on emerging data;
- Supporting clinical development of our partnered candidate, dapolsertib (MEN1703, SEL24) by Menarini Group;
- Strengthening Company's discovery pipeline and accelerating progress using first in class novel small molecule precision medicine approach via our proprietary ONCO Prime platform, as well as antibody-drug conjugates (ADCs) with novel payloads.;
- Achieving financial milestones in the existing R&D collaborations (i.e. BioNTech, Exelixis, Menarini);
- Advancing business development activities for fully owned programs, including romaciclib, involving structured discussions with potential partners regarding licensing, co-development, and option arrangements across multiple markets, with the objective of concluding a partnering transaction upon achievement of pre-specified clinical data milestones from the RIVER-81 expansion cohort.

Explanations regarding the seasonal or cyclical nature of the Issuer's operations in the reported period

Not applicable.

Information on inventory write-downs to the net realizable amount and reversal of such write-downs

Not applicable.

Information on impairment write-downs in respect of financial assets, tangible fixed assets, intangible assets or other assets and the reversal of such write-downs

Not applicable.

Information on the set-up, increase, utilization and reversal of provisions

Information on the changes in provisions for holidays and bonuses is provided in note 17 to the financial statements.

Information on deferred income tax provisions and assets

No significant changes.

Information on significant purchases or disposals of tangible fixed assets

No significant changes.

Information on significant liabilities in respect of purchases of tangible fixed assets

No significant changes.

Information on significant settlements resulting from court cases

Not applicable.

Error corrections relating to previous periods

Not applicable.

Information on changes in the economic situation and business conditions, which have a significant effect on the fair value of the entity's financial assets and financial liabilities

Not applicable.

Information on the failure to repay a loan or borrowing or a breach of significant terms and conditions of a loan agreement, with respect to which no corrective action had been taken by the end of the reporting period

Not applicable.

Information on changes in the method of valuation of financial instruments measured at fair value

Not applicable.

Information on changes in the classification of financial assets due to a change in their purpose

Not applicable.

Information on the issue, redemption and repayment of non-equity and equity securities

Not applicable.

Information on dividends paid (or declared) in the total amount and per share, divided into ordinary and preference shares

Not applicable.

Events that occurred after the date for which the quarterly financial statements were prepared, not disclosed in these financial statements, although they may have a significant effect on the Issuer's future financial results

Not applicable.

Information on changes in contingent liabilities or contingent assets that occurred after the end of the last financial year

Information on changes in contingent liabilities or contingent assets is provided in note 22 to the financial statements.

Other disclosures that may have a material impact on the assessment of the Issuer's financial position and results of operations

Not applicable.

Amounts and types of items affecting the assets, liabilities, equity, net profit/ (loss) or cash flows, which are unusual in terms of type, amount, or frequency

Not applicable.

Krakow, May 20, 2026

Dokument podpisany przez Paweł Tadeusz Przewięźlikowski
Data: 2026.05.20 15:04:01 CEST

Paweł Przewięźlikowski
President of the Management Board

Dokument podpisany przez Krzysztof Daniel Brzózka
Data: 2026.05.20 14:27:36 CEST

Krzysztof Brzózka
Vice-President of the Management Board

Dokument podpisany przez Kamil Sebastian Sitarz
Data: 2026.05.20 14:05:37 CEST

Kamil Sitarz
Management Board Member

Digitally signed by Vatnak Vat-Ho
Date: 2026.05.20 09:12:12 MDT

Vatnak Vat-Ho
Management Board Member

Signed by / Podpisano przez:
FRANZ HENDRIK DR. NOGAI
Date / Data: 2026-05-20 16:13

Hendrik Nogai
Management Board Member

Elektronicznie podpisany przez Justyna Katarzyna Żółtek
Data: 2026.05.20 15:36:36 +02'00'

Justyna Żółtek
Management Board Member

CONTACT

RYVU THERAPEUTICS

2 Sternbacha Street

30-394 Krakow, Poland

P: +48 12 314 02 00

GENERAL INQUIRIES

ryvu@ryvu.com

RYVU THERAPEUTICS